MyAmyloidosisTeam

Wainua (eplontersen) was recently approved by the FDA for treating hereditary ATTR amyloidosis with polyneuropathy. This is a newer treatment option that has received Fast Track designation from the FDA, indicating its potential importance in treating amyloidosis.

While it's still early to have extensive feedback since its Show Full Answer

Wainua (eplontersen) was recently approved by the FDA for treating hereditary ATTR amyloidosis with polyneuropathy. This is a newer treatment option that has received Fast Track designation from the FDA, indicating its potential importance in treating amyloidosis.

While it's still early to have extensive feedback since its recent approval, the drug has shown promising results in clinical trials. As with any new medication, it's important to discuss with your healthcare provider whether this treatment option might be appropriate for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

hATTR Amyloidosis Treatments: Comparing Your Options